Suraksha Diagnostic Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹13(2.95%)
Premium (ELP)
The public market debut of Suraksha Diagnostic Limited's was completed on Dec 06, 2024 with its listing on the NSE, BSE exchange. The IPO process raised 1,91,89,330 Shares in total capital, consisting of TBD in new equity and ₹846.25 Cr in existing share sales through the OFS route.
The offering featured a price range of ₹420 to ₹441 and minimum application size of 34 shares. Investor response during the subscription period from Nov 29, 2024 to Dec 03, 2024 influenced the final allotment ratios across investor categories.
Final allotment was announced on Dec 04, 2024, distributing shares to successful subscribers. The listing established a continuous market for the company's shares, enabling liquidity, valuation transparency, and broader investor participation.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Suraksha Diagnostic Limited, incorporated on March 15, 2005, is a technology-driven diagnostic chain offering integrated pathology, radiology, and medical consultancy services. The company provides over 2,300 tests across multiple specialties through a network that includes a central reference laboratory, 8 satellite laboratories, and 194 customer touchpoints, comprising 48 diagnostic centers and 146 sample collection centers. Additionally, 43 diagnostic centers house 120 polyclinics staffed by over 750 doctors, providing online and offline consultations. Leveraging advanced technology such as LIMS, RIS, PACS, and ERP systems, Suraksha Diagnostic enhances operational efficiency and reduces turnaround times. The company also offers vaccination services, customized testing packages for early disease detection, and AI-driven digital pathology solutions, with all radiology reports digitally processed to enable seamless reporting across centers.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Strong Market Position: Leading diagnostics chain in eastern and northeastern India with growth potential in a fragmented market.
- Comprehensive Offerings: Integrated pathology, radiology, and medical consultancy services with a wide network of diagnostic and sample collection centers.
- Technological Edge: Advanced clinical infrastructure with digital pathology, AI-driven diagnostics, and efficient systems including LIMS, RIS, PACS, and ERP.
- Geographic Concentration: Heavy reliance on West Bengal for 95.48% of revenue makes the company vulnerable to regional disruptions affecting operations and financial performance.
- Promoter Group Issues: Past suspension of securities of certain Promoter Group members raises reputational concerns and may complicate future capital raising.
- Intense Competition: Operating in a competitive diagnostics industry with a modest market share (1.15–1.30% in East India) could restrict growth and profitability.
- Dr. Somnath Chatterjee
- Ritu Mittal
- Satish Kumar Verma
Suraksha Diagnostic Limited
Kfin Technologies Limited